Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review. - Suppr | 超能文献

Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review.

作者信息

Serebruany Victor L

机构信息

HeartDrug Research Laboratories, Johns Hopkins University, Towson, MD 21204, USA.

出版信息

Am J Ther. 2012 Mar;19(2):160-1. doi: 10.1097/MJT.0b013e318245ce6c.

DOI:10.1097/MJT.0b013e318245ce6c

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Peripheral vascular outcomes in the PLATO trial: update from the FDA ticagrelor complete response review.

Am J Ther. 2012 Mar;19(2):160-1. doi: 10.1097/MJT.0b013e318245ce6c.

2

The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.PLATO试验中替卡格雷或氯吡格雷用药后不良事件报告的FDA展望：申办方审查日期、药物停用及撤回同意书的影响

Cardiology. 2011;120(3):169-71. doi: 10.1159/000335476. Epub 2012 Jan 5.

3

Ticagrelor: a new option for ACS.替格瑞洛：急性冠状动脉综合征的新选择。

Nurse Pract. 2012 Mar 13;37(3):9-11. doi: 10.1097/01.NPR.0000411112.79443.04.

4

Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.2010年美国食品药品监督管理局心血管和肾脏药物咨询委员会关于替格瑞洛的会议概述。

Circulation. 2011 Feb 1;123(4):451-6. doi: 10.1161/CIRCULATIONAHA.110.985325. Epub 2011 Jan 17.

5

Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.评估直接作用的 P2Y(12)抑制剂替卡格雷在急性冠脉综合征中的风险效益比。

Postgrad Med. 2011 Nov;123(6):79-90. doi: 10.3810/pgm.2011.11.2498.

6

Ticagrelor for acute coronary syndromes.替格瑞洛用于急性冠状动脉综合征

Expert Rev Cardiovasc Ther. 2013 Nov;11(11):1473-84. doi: 10.1586/14779072.2013.839205. Epub 2013 Oct 23.

7

Ticagrelor: from discovery to Phase III clinical trial.替格瑞洛：从发现到III期临床试验

Future Cardiol. 2010 Nov;6(6):753-64. doi: 10.2217/fca.10.89.

8

Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.替格瑞洛与氯吡格雷用于行冠状动脉旁路移植术的急性冠状动脉综合征患者：来自 PLATO（血小板抑制和患者结局）试验的结果。

J Am Coll Cardiol. 2011 Feb 8;57(6):672-84. doi: 10.1016/j.jacc.2010.10.029. Epub 2010 Dec 30.

9

Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial?腺苷释放：替格瑞洛在 PLATelet inhibition and clinical outcomes trial 中获益的潜在解释？

Am Heart J. 2011 Jan;161(1):1-4. doi: 10.1016/j.ahj.2010.09.017.

10

Ticagrelor FDA approval issues revisited.

Cardiology. 2012;122(3):144-7. doi: 10.1159/000339470. Epub 2012 Jul 24.

引用本文的文献

1

A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.一种新型的急性冠状动脉综合征经皮冠状动脉介入治疗患者的降阶抗血小板治疗。

Medicine (Baltimore). 2023 Jul 7;102(27):e34153. doi: 10.1097/MD.0000000000034153.

2

Antiplatelet agents for chronic kidney disease.抗血小板药物在慢性肾脏病中的应用。

Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4.